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Infectious salmon anemia (ISA) virus is an emerging pathogen of fanned Atlantic 
salmon. Due to the massive economic losses inflicted by the ISA virus, effective 
measures to control future outbreaks are necessary. An attractive method for preventing 
ISA virus from infecting stocks of Atlantic salmon is vaccination. DNA vaccination is a 
proven cheap, effective means of protecting fish from aquatic viruses. In this thesis DNA 
vaccination of Atlantic salmon was investigated. Three different strains of ISA virus 
were cultured and purified by density gradient ultracentrifugation. ISA virus RNA was 
isolated and used to amplify full-length cDNAs of five ISA virus segments. These 
segments were cloned into hCMV vectors and recovered using an ammonium acetate 
precipitation reaction. DNA vaccines containing full-length ISA virus segments were 
used to vaccinate rainbow trout and Atlantic salmon. The DNA vaccines were tested for 
their ability to provide cross-protection, persistent immunity, and a humoral immune 
response. These vaccines were also compared to whole killed ISA virus vaccines and 
recombinant peptide vaccines derived from ISA virus surface proteins. 
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Chapter 1 
INTRODUCTION 
Infectious Salmon Anemia Virus 
Classification 
Infectious salmon anemia (ISA) is a disease of farmed Atlantic salmon (Salmo 
salar). The etiological agent of ISA has been shown to be a pleomorphic, enveloped 
virus 100-130 nm in diameter (Hovland et al., 1994). It has been shown that ISA virus 
(ISAV) possesses a negative sense single stranded RNA genome consisting of eight 
segments 1-2.3 kb in size which would be consistent with an orthomyxovirus (Mjaaland 
et al., 1997). Sequence comparisons of the polymerase sequence of ISA virus to that of 
other orthomyxoviruses suggests that ISA virus should be classified under a fifth, new 
genus within the Orthomyxoviridae family of viruses (Krossoy et al., 1999). 
Phylogenetic calculations reveal that ISA virus is more closely related to influenza 
viruses than to Dhori and Thogoto viruses (Krossoy et a]., 1999). 
Geo~raphic Distribution 
ISA was first observed in Norway in 1984 and is believed to have been present as 
early as the 1970's (Thorud & Djubvik et a]., 1988). ISA has been reported in the United 
Kingdom (Scotland) (Rodger et al., 1998), New Brunswick, Canada (Bouchard et al., 
1999) and in the United States off the coast of Maine (Cobscook Bay) (Clancey, 2001). 
ISA virus has recently been isolated in Chile from Coho salmon (Oncorhynchus kisutch) 
exhibiting symptoms of ISA (Kibenge et al., 2001). The manner in which ISA virus is 
introduced from one area to another can be the result of many factors including, 
transportation of infected fish between fish farms or infection from other species that act 
as asymptomatic carriers. (Krossoy et al., 2001a). 
Host R a n ~ e  and Susceptibilitv 
The primary host of ISA virus is farmed Atlantic salmon (Salmo salar) and it has 
also been shown to replicate in rainbow trout (Oncorhynchus mykiss) (Nylund et al., 
1997). Although ISA virus does not cause disease in this species, infected rainbow trout 
exhibit lower levels of red blood cells and petechiae on the liver (Nylund et al., 1997). 
Brown trout (Salmo trutta) can also act as asymptomatic carriers of ISA virus (Nylund et 
al., 1994). ISA virus has recently been isolated from Coho salmon (Oncorhynchus 
kisutch) exhibiting symptoms of ISA (Kibenge et al., 2001), suggesting that ISA virus 
can cause disease in species other than Atlantic salmon. Studies have shown that ISA 
virus can agglutinate erythrocytes from rainbow trout, Atlantic salmon, Atlantic cod 
(Gadus morhua), and crucian carp (Carassius caraccius) with varying affinities (Falk et 
al., 1997). 
Transmission 
The manner in which ISA virus is transmitted from one area to another is not yet 
known. Horizontal transmission studies have shown that cohabitation of uninfected 
Atlantic salmon with ISA virus-infected Atlantic salmon results in the spread of the ISA 
virus to uninfected fish (Thorud & Djubvik et al., 1988; Jones & Groman, 2001). As 
stated above, other species of fish can act as reservoirs for ISA virus while not exhibiting 
signs of disease. Populations of wild Atlantic salmon may also act as virus reservoirs and 
mediate the spread of ISA virus through migratory movement. However, the migration 
patterns of these fish are not well established and the presence of ISA virus within 
populations of wild fish has not yet been investigated. Studies have suggested that the 
spread of ISA virus may be linked to transfer of fish fiom one fish fami to another 
(Krossoy et al., 2001a). There is also evidence that sea lice (Lepeophtheirus salmonis) 
may play a role in transmission (Nylund et al., 1993). 
Vertical transmission of the ISA virus has been investigated (Melville and 
Griffiths, 1999). Atlantic salmon eggs collected fiom fish identified as ISA virus- 
positive were fertilized and reared. The eggs and parr were screened for ISA virus by 
SHK-1 cell culture and RT-PCR. ISA virus was not detected in eggs or parr and no 
mortalities due to the virus were apparent. These observations suggest that ISA virus 
infection does not occur as a result of vertical transmission. 
Pathology ( s i ~ n s  and symptoms) 
The pathology of ISA virus has been characterized (Evensen et al., 1991). 
Symptoms of infectious salmon anemia include ascites and congestion of the foregut in 
the early stages. As infection moves fiom early to mid stage, progressive anemia is 
observed as indicated by lower haematocrit values. Congestion of the spleen and liver 
occur with the liver being more severely affected. Dissemination of liver lesions 
increases gradually as haematocrit values decrease. During later stages of infection, liver 
degeneration is characterized by lower levels of hepatocytes and haemorrhagic necroses 
with the majority of lesions located on the parenchyma and the vascular system of the 
liver. 
The presence of ISA virus in the head kidney, liver, spleen, heart, intestine, gill, 
and muscle organs of Atlantic salmon over the course of infection has been investigated 
(Rimstad et al., 1999). Organs from ISA virus infected fish have been examined by RT- 
PCR at 1, 2, 5, 6, 8, 13, 16, 20, 27, 34, and 40 days post infection (DPI). ISA virus is 
detected as early as 1 dpi in at least one fish and at all other time intervals examined. ISA 
virus is detected predominantly in the head kidney and mid-kidney from 1 to 8 dpi. At 13 
dpi ISA virus is found in all organs sampled indicating that the ISA virus replicates most 
substantially between 8 and 13 dpi. 
Cell Culture of ISA Virus 
Isolation and purification of ISA virus was initially hampered by the fact that the 
virus did not seem to replicate in cell lines routinely used to isolate fish viruses. In 1994 
the long term cell line SHK-1 was derived from salmon head kidney cells. SHK-1 cells 
support ISA virus growth (Dannevig et al., 1995) but the cell line requires precise 
growing conditions and is difficult to work with. ISA virus can also be propagated in 
Chinook salmon embryo (CHSE-214) cells, a more commonly used cell line that requires 
less stringent growth and maintenance conditions (Bouchard et al., 1999; Lovely et al., 
1999; -Kibenge et al., 2000). Other cells that support ISA virus growth are Atlantic 
salmon kidney (ASK) cells (Krossoy et al., 1999). 
Genome and Genomie Orpanization 
ISA virus possesses a single-stranded, negative sense RNA genome 14.5 kb in 
length (Mjaaland et al., 1997) consisting of eight segments 1.0-2.3 kb in length that 
encode ten different proteins (Clouthier et al., 2002). The ISA viral genome is organized 
according to the length of each segment from largest to smallest (Table 1.1). 
Comparisons of ISA viral sequences to those listed in the Influenza database and 
in Genbank showed that FZNA segments 1 and 5 are unique. FZNA segments 2,3,4,  and 6 
encode the putative proteins PBl, NP, PA, and HA, respectively. Segments 7 and 8 each 
have two open reading frames (OW). Segment 7 encodes proteins P4 and P5 and 
segment 8 encodes proteins P6 and P7. A recent study by Biering et al. (2002) suggests 
that the nonstructural (NS) protein of ISA virus is encoded by genome segment 7 and the 
matrix protein by genome segment 8. 
The complete sequence of segment 1 of ISA virus has not yet been reported. The 
gene product is protein PI. Its function has not yet been determined. Northern blot 
analysis of this segment indicates that it is approximately 2.4 kb in length (Clouthier et 
al., 2002). 
Segment 2 of ISA virus is 2.4 kb in length with a 2245 bp ORF encoding a 708 
amino acid polypeptide with an estimated molecular mass of 80.5 kDa. Sequence data of 
this segment compared with that of influenza sequences reveals that this protein is the 
PBl protein (Krossoy et al., 1999). In influenza viruses, PB1 is one of three subunits that 
comprise the viral FZNA-dependent FZNA polymerase. Comparison of the PBl amino 
acid sequence of the Charley cove back bay (CCBB) isolate of the ISA virus (AF404346) 
reveals that it is 82.2% and 84.5% identical to the PBl amino acid sequence of the 
Norwegian (AJ002475) and Scottish (AF262392) isolates of the ISA virus, respectively. 
Segment 3 is comprised of a 2.2 kb sequence with a 185 1 bp ORF encoding a 617 
amino acid polypeptide with an estimated molecular mass of 68.0 kDa (Clouthier et al., 
Table 1.1 RNA segments of ISA virus and their encoded proteins. 
Segment Length (kb) Encoded protein* Predicted molecular mass (kDa) 
- 
* Encoded Proteins are as follows: P1 = Protein 1 ; PB1 = Polymerase Binding 
Protein 1; NP = Nucleoprotein; P2 = Protein 2; P3 = Protein 3; HA = 
Haemagglutinin; P4 = Protein 4; P5 = Protein 5; P6 = Protein 6; P7 = Protein 7 
2002). Conserved features and amino acid sequence similarities of this segment 
compared with that of influenza sequences reveal that this segment encodes 
nucleoprotein (NP) (Snow and Cunningham, 2001). NP of influenza viruses binds to the 
viral RNA genome forming the nucleocapsid. Comparison of the NP amino acid 
sequence of the CCBB isolate of ISA virus (AF404345) reveals that it is hlghly 
conserved, sharing 96.6% identity to the NP amino acid sequence of the Scottish isolate 
(AJ276858) (Clouthier et al., 2002). 
Segment 4 consists of a 1.9 kb sequence with a 1737 bp ORF that encodes a 579 
amino acid polypeptide with an estimated molecular mass of 65.3 kDa (Clouthier et al., 
2002). The gene product of ISA virus segment 4 is protein P2. Its function has not yet 
been determined. Translation of the ORF of segment 4 of ISA virus isolate CCBB 
(AF404344) reveals that it is highly conserved, sharing 99% identity to the putative PA 
amino acid sequence (AF306548) described by Ritchie et al. (2001) (Clouthier et al., 
2002). In influenza viruses, PA is one of three subunits that comprise the viral RNA- 
dependent RNA polymerase. 
Segnlent 5 is 1.6 kb in length with a 1353 bp ORF that encodes a 45 1 amino acid 
polypeptide with an estimated molecular mass of 49.8 kDa (Clouthier et al., 2002). The 
gene product of ISA virus segment 5 is protein P3. Its function has not yet been 
determined. However, the P3 protein has a 17 amino acid N-terminal signal sequence 
and several potential glycosylation sites, suggesting a virion surface location (Clouthier et 
al., 2002). P3 is likely the acetylesterase involved in receptor-destroying activity. The 
nucleotide sequence of segment 5 of ISA virus isolate CCBB (AF404343) is 76.0%, 
76.4% and 99.7% similar to segment 5 of the Norwegian (AF429987), Scottish 
(AF429988), and Maine (AF429986) isolates of ISA virus, respectively. 
Segment 6 of ISA virus is a 1.5 kb sequence with a 1185 bp ORF that encodes a 
395 amino acid polypeptide with an estimated molecular mass of 43.1 kDa (Clouthier et 
al., 2002). Salmon cell lines engineered to express segment 6 gain the ability to bind 
salmon erythrocytes, identifying this segment as that encoding the hemagglutinin (HA) 
(Krossoy et al., 2001b; Rimstad et al., 2001). The HA forms 13-15 nrn spikes that coat 
the surface of the pleomorphic, enveloped virus (Falk et al., 1997). The HA is thought to 
be involved in ISA virus binding to sialic acid cell surface receptors and fusing with the 
cell in acidic endosomes (Eliassen et al., 2000). Comparison of the HA amino acid 
sequence of ISA virus isolate CCBB (AF404342) reveals that it shares 84.8 and 84.3% 
similarity to the predicted HA protein sequences for ISA virus isolates fi-om Norway 
(AF302799) and Scotland (AJ276859) and 99.2% similarity to the Maine ISA virus 
isolate (AY059402). 
Segment 7 of ISA virus is a 1.3 kb sequence with two ORFs. The first ORF is 
771 bp encoding a 257 amino acid protein with an estimated molecular mass of 28.6 kDa. 
The second ORF is 441 bp encoding a 147 amino acid protein with an estimated 
molecular mass of 16.3 kDa (Clouthier et al., 2002). The gene products of the first and 
second ORFs of segment 7 of the ISA virus are proteins P4 and P5, respectively. Biering 
et al. (2002) suggested that the colinear transcript encodes a non-structural or minor 
structural protein. The nucleotide sequence for the ISA virus CCBB segment 7 
(AF404341) share; 99.6% similarity to a p~eviously reported sequence from a Scottish 
isolate of ISA virus (AX083264). 
Segment 8 of ISA virus is a 1.0 kb sequence with two OW. The first O W  is 705 
bp encoding a 235 amino acid protein with an estimated molecular mass of 26.5 kDa. 
The second O W  is 552 bp encoding a 184 amino acid protein with an estimated 
molecular mass of 20.3 kDa. The gene products of the first and second OWs of segment 
8 are proteins P6 and P7, respectively. Biering et al. (2002) suggested that segment 8 
encodes a structural protein. The nucleotide sequence of segment 8 of CCBB ISA virus 
isolate (AF404340) shares 88.7 and 99.9% identity to the Norwegian (AF429990) and 
ME101 (AF429989) isolates of ISA virus, respectively. 
Infectious Hernatopoietic Necrosis Virus (IHNV) 
Infectious hematopoietic necrosis (IHN) is a disease of salmon and trout. The 
etiological agent of IHN is a bullet shaped, enveloped virus 1 10- 160 nm in length and 70- 
90 nm in width. The IHN virus is classified as a member of the Rhabdoviridae family of 
viruses under the genus Novirhabdovirus (Walker et al., 2000). The IHN virus has a 
geographic range from Alaska to California and extending inland to Idaho, it has also 
been reported in Europe and Asia (Winton, 1991). This virus causes disease in wild and 
fanned rainbow trout, pacific salmon (Oncohrynchus keta), steelhead (Oncorhynchus 
mykiss), and Atlantic salmon, with the highest mortalities usually occurring in juvenile 
fish. The IHN viral genome is a single-stranded, negative sense RNA, approximately 
1 1,130 bp long (Morzunov et al., 1995). It encodes 6 proteins: the nucleoprotein (N), the 
matrix proteins (MI and M2), the non-virion protein (NV), the polymerase protein (L), 
and the glycoprotein (G). Virus particles of the IHN virus are covered with the G protein, 
which is a major surface antigen that stimulates a protective inlrnune response in 
salmonids (Corbeil et al., 1999; Engelking and Leong, 1989a; Lorenzen and LaPatra, 
1999; Winton, 1997). 
Control of the ISA virus 
Chemical and Physical Inactivation of the ISA virus 
The salmon fanning industry can incur massive economic losses due to the ISA 
virus. To prevent this, steps to minimize its impact on the aquaculture industry are being 
taken. ISA virus survives in sea and fresh water for more than 48 hours, but virus 
infectivity diminishes between 24 and 48 hours. Since tissue from infected salmon is 
highly contagious (Flogstad et al., 1991), it is necessary for intake water and wastewater 
of slaughtering plants to be treated for ISA virus. To this end, the chemical and physical 
inactivation of ISA virus in free water and wastewater from the slaughtering process has 
been investigated (Flogstad et al., 199 1 ; Flogstad & Torgersen, 1992). Practical methods 
for chemical inactivation of ISA virus involve treating water sources with sodium 
hydroxide, sodium hypochlorite, and formic acid. ISA virus infectivity is lost in the 
presence of 56 1 M  formic acid for 8 hours, 1 mM sodium hydroxide at for 48 hours or 
pH 12.0 for 24 hours, or 1.35 rnM sodium hypochlorite for 15 min. Other methods of 
ISA virus inactivation investigated include ultraviolet (UV) irradiation or heat treatment 
of water. These methods present an attractive alternative to the use of harmful chemicals. 
ISA virus infectivity is lost in water heated to temperatures of 50 "C or higher for 2 min 
or water irradiated with UV light at a dose of 4 m ~ / c m ~  or higher. 
Husbandrv 
Atlantic salmon must be raised in an ISA virus free environment to prevent virus 
propagation. Visitors to an aquaculture facility are required to wear disposable "pull on" 
shoes to prevent the introduction of contaminants. Visitors are not allowed to come into 
contact with intake water or food dispensers. When moving from one area of the facility 
to another visitors and staff are required to step into footbaths containing disinfectant. 
Equipment entering and leaving the facility are disinfected. Small items such as nets are 
cleaned using a high-pressure cleaning device to remove visible contaminants and then 
washed with the appropriate disinfectant. Tires of fish transport vehicles and boats used 
at sea based facilities are similarly treated. All holding pens and pipes must be non- 
absorbant. Pipes and holding pens on farms and transport vehicles must be treated by 
first eliminating visible contaminants such as algae using a high-pressure device and then 
washing with an appropriate disinfectant by mechanical scrubbing. Seawater 
installations are dissembled and dried before they are disinfected. Tanks that consist of 
material that is porous, such as fiberglass and non-painted concrete, are treated with low- 
pressure devices and cleaned by mechanical scrubbing with an alkaline detergent from 
the top to the bottom of the tank. 
The movement and rearing of fish is highly controlled. Any outbreaks of ISA 
virus are reported within four days to ensure that proper precautionary measures can be 
implemented. ISA combat zones have been established in Norway where strict 
regulations are applied to prevent the spread of the ISA virus. The movement of fish 
from sites where the ISA virus has been verified into "ISA combat" zones is prohibited. 
Stocks of fish entering a farm from another facility may be quarantined for a period of 
time. Fish eggs are disinfected with Iodophor at a pH of 6-8 to prevent infection of new 
stocks. Fish are carefully monitored for possible outbreaks. Dead fish are removed, 
tested for the ISA virus, and processed to prevent possible contamination. Crops of 
Atlantic salmon exhibiting ISA virus symptoms are immediately slaughtered to prevent 
further spread of the disease to other fish pens. The fish pens where the ISA virus has 
been detected are restocked only after being disinfected and quarantined. 
Genetic Immunization 
DNA Vaccination 
Proper treatment of contaminated equipment and close monitoring of the rearing 
and transport of fish are two methods of controlling ISA virus. Vaccination of fanned 
Atlantic salmon against ISA virus offers an additional effective method for controlling 
this pathogen. Inactivated whole virus ISA vaccines and peptide vaccines composed of 
ISA virus protein subunits or recombinant peptides are being tested. 
In 1993, researchers developed a new form of vaccination called the DNA 
vaccine (Ulmer et al., 1993). DNA vaccination consists of injecting the host with a 
circular piece of DNA containing the gene for an immunogenic protein. This results in 
the host cell expressing the foreign protein and the immune system recognizing it. In 
many cases, this results in a better immune response than peptide or whole killed 
vaccines, presumably because the antigenic protein is syntheshed in the host in situ in a 
manner that more closely mimics its synthesis during a natural infection. DNA vaccines 
are desirable over other forms of vaccination because they are cheap, easy to synthesize, 
and activate both humoral and cell-mediated branches of the immune system (Fynan et 
al., 1993; Ulmer et al., 1993). 
DNA Vaccination of Fish 
In 1996, the first DNA vaccine for fish was described (Anderson et al., 1996b). 
In this study, intramuscular injection of a plasmid containing the gene encoding IHN 
virus G protein (IHNV-G), under the control of the human cytomegalovirus (hCMV) 
promoter, protected rainbow trout fry fiom homologous virus challenge at 28 days post- 
vaccination (DPV) (Anderson et al., 1996b). The G protein also elicits a nonspecific, 
cross protective immune response in rainbow trout that begins 4-7 d post-vaccination 
(LaPatra et al., 2001). Fish antibodies do not mediate the early viral response (EVR) but 
are detectable in fish approximately 3-4 weeks after vaccination (LaPatra et al., 1993). 
The appearance of serum antibodies coincides with the loss of the EVR and the 
appearance of a specific viral response (SVR). The SVR results in 90-100% relative 
percent survival (RPS; RPS = (1 - (% Mortality of Vaccine1 % Mortality of Negative 
Control)) X 100) of fish vaccinated with the IHN virus DNA vaccine pIHNw-G, for 1-3 
months post-vaccination, 69% RPS 6 mo post-vaccination, and 65% RPS 13 mo post 
vaccination. Thus, protection at the early time points is more likely the result of a cell- 
mediated immune response or non-specific anti-viral reaction that fbnctions to protect the 
host at the onset of infection. 
Another example of an aquatic DNA vaccine is the viral haemorrhagic 
septicaemia virus glycoprotein (VHSV-G) DNA vaccine (Lorenzen et al., 1999). This 
vaccine protects rainbow trout from infection and stimulates high levels of virus specific 
neutralizing antibodies (Boudinot et al., 1998). The VHSV-G DNA vaccine provides 
protection as early as 7 days post vaccination and stimulates Mx and MHC class I1 
mRNA production (Boudinot et al., 1998). Protection at these early time points and the 
activation of these genes indicates that the VHSV-G DNA vaccine may stimulate the 
same non-specific, cell-mediated immune response as the MNV-G DNA vaccine. 
The EVR defense mechanism stimulated by IHNV-G and VHSV-G DNA 
vaccines has not been characterized. In rainbow trout, both vaccines stimulate production 
of Mx and MHC class I1 rnRNA as early as 7 dpv (Boudinot et al., 1998). In mammals, 
synthesis of these proteins is induced by interferon and the products play critical roles in 
cell-mediated immunity. Other types of early non-specific immune responses in fish 
have been observed. The VHSV-G DNA vaccine induces synthesis of VHSV induced 
gene (VIG) 7days post injection. The VIG protein may be involved in the production of 
enzymatic cofactors of the nitric oxide pathway (Boudinot et al., 1999). The connection 
between nitrogen metabolism and resistance to viral pathogens is unknown. VIG-2 is a 
new interferon-responsive gene induced by exposure of rainbow trout to VHS virus 
(Boudinot et al., 2001). Type 1 interferon-like activity has also been observed in fish 
cells as early as 48 hours afier being exposed to IHN virus or poly I:C (Eaton et al., 1990; 
Trobridge et al., 1997). The ability of ISA virus segments to stimulate the same type of 
early non-specific response was investigated as part of my thesis studies. 
Vaccine Strategies 
The efficacy of DNA vaccination of Atlantic salmon against the ISA virus has not 
yet been investigated. To this end several DNA vaccines containing ISA virus segments 
3, 5, 6, 7, and 8 were created and tested in the following vaccine trials. The ability of 
these vaccines to protect rainbow trout and Atlantic salmon from lethal challenges of 
IHN and ISA virus was tested. Serum samples were collected from vaccinates to 
measure the production of antibodies. The data from these trials helped to determine 
which ISA virus gene segments produced irnrnunoreactive peptides, which ones are cross 
protective, which ones produce an antibody response, and the kinetics of that response. 
These trials also helped to determine if ISA viral genes can induce in Atlantic salmon the 
same type of early non-specific cell-mediated immune response seen with the MNV-G 
and VHSV-G DNA vaccines in rainbow trout. Also included in these trials were 
different types of whole killed virus and peptide vaccines so that their efficacy could be 
compared with that of the DNA vaccines. 
A further question addressed in these trials is the possibility that ISA virus 
contains an immunosuppressive protein. Recent studies have shown that the NSl protein 
of influenza A virus inhibits alphaheta interferon production by preventing the activation 
of NF-KB (Wang et al., 2000). In the mammalian system, secretion of alphaheta 
interferon represents the first line of defense against viral infection. Due to the 
similarities between influenza viruses and ISA virus it is possible that the ISA virus 
possesses a gene that has a similar immunosuppressive function. It is not yet known 
which segment of the ISA viral genome encodes a similar NS1 protein. Segment 7 and 8 
are the most suspect genes because they are most similar in length and both contain two 
open reading frames like the NS gene of influenza viruses. The possibility that either 
ISA virus segments 7 or 8 encode an immunosuppressive protein was investigated using 
the MNV-G DNA vaccine as a determinant. 
Chapter 2 
METHODS 
Virus and Cell Line 
ISA virus was isolated from farmed Atlantic salmon. The North American ISA 
virus isolates CCBB and Comer have previously been described (Clouthier et al., 2002). 
The European isolates (Glesvaer 2/90 Norway, and 390198 Scotland) were kindly 
provided by Dr. Knut Falk and Dr. Katrinna Ross, respectively. The ISA virus was 
grown in Chinook salmon embryo (CHSE-2 14) cells (Lannan et al., 1984) at 15 OC in 
minimal essential medium (MEM) containing Hank's salts (Gibco BRL), 10 mM L- 
glutamine and 10% fetal bovine serum (Gibco BRL). 
Virus and RNA Purification 
ISA virus was purified from the supernatant of virus infected CHSE-214 cells 
showing complete cytopathic effect (CPE). The virus supernatant was filtered using a 
sterile Suporcap-50 0.45 micron filter (Gelman). The virus supernatant was placed in 
Specpore 7 tubing (Spectrum Laboratories) and dialyzed for 8 hr at 4 OC against PEG 
8000 (Sigma). The concentrated virus supernatant was centrifuged for 2 hr at 104,000 g 
in a Beckman SW-28 rotor using a Beckman L8-70M ultracentrifuge. The crude virus 
pellet was resuspended in 1 ml TNE (10 mM Tris pH 7.5, 100 mM sodium chloride and 1 
mM EDTA, pH 7.5) and layered onto a 25-35-45% discontinuous sucrose gradient and 
centrifuged for 3 hr at 132,000 g in a Beckman SW28 rotor using a Beckman L8-70M 
ultracentrifuge. The virus was collected from the 35-45% interface, diluted in TNE and 
centrifuged for 2 hr at 104,000 g in a Beckman SW-28 rotor using a Beckrnan L8-70M 
ultracentrifuge. The virus pellet was then resuspended in 0.5 ml of TNE. 
cDNA Svnthesis 
ISA virus genomic RNA was prepared using Trizol (Invitrogen Corp.), and 
converted into cDNA by reverse transcription. Purified viral RNA (500 ng), was mixed 
with 2.5 pM forward and reverse oligonucleotide primers (Table 2.1) and 40 U of RNase 
Out (Gibco BRL) were combined and incubated at 72 "C for 2 min. A solution of, 625 
mM dNTPs, 6.25 mM of dithiothreitol, 100 U of Superscript I1 reverse transcriptase (all 
Gibco BRL) were added to the solution and the mixture was incubated at 22 "C for 10 
min and then 42 "C for 1 hr. 
The polymerase chain reaction (PCR) was used for second strand cDNA 
synthesis. First strand cDNA was combined with PCR reaction buffer, 10 pmol dNTP, 
100 pmol magnesium chloride, 50 pmol forward and reverse oligonucleotide primers 
(Table 2.1) and 5 U of Taq polymerase (all Gibco BRL). The mixture was incubated at 
95 "C for 2 min and then for 35 cycles at 95 "C for 1 min, 50 "C for 1 min and 72 "C for 
2 min followed by 72 "C for 10 min. The PCR amplified cDNA was separated in a 1.5% 
agarose gel (Sigma) in a RAGE-100 (Cascade Biologics) apparatus and purified using a 
the Qiaquick Gel Extraction Kit (Qiagen Inc.) as described by the manufacturer (Qiagen 
Inc .). 
Table 2.1 Primers used to amplify fill-length ISA virus segments. 
Segment Primers Sequence 5'-3' 
Segment 3 pTargeT-NP-For CGCATAATAGGATCCGCAAAG 
ATTGCTCAAATCCCAAAAATA 
pTargeT-NP-Rev CATGCTCAAGGTACCTGTAAA 
TATCGTCAATACCGTTTC 
Segment 5 5E7FullF 
5E7FullR 
Segment 7 2B10F1 
2B10R1 
AGTTAAAGATGGCTTTTCTAAC 
CTATTTATACAATTAATAATG 
CATAATC 
TACAAAGAAAATGTTCAGAAC 
ATGTCTG 
AAAAATTATCATCAACACCAT 
GTACGAC 
Segment 8 Class 2 AAGCAGTGGTAACAACGCAGA 
CTGTATCTACCATG 
Seg8-3-R-mRNA TTATTGTACAGAGTCTTCC 
DNA Vaccines Plasmids 
ISA virus cDNA segments 3, 5, 7 and 8 were ligated into pGEM-T (Table 2.2) as 
described by the manufacturer (Promega Corp.) and cDNA segments 6, 7, and 8 were 
ligated into pTargetT (Table 2.3) as described by the manufacturer (Promega Corp.) The 
ISA virus cDNA clones were amplified using E. coli JM109 cells (Sambrook et al., 
1989). Verification that the plasmids contained full length ISA virus cDNA was done by 
DNA sequence analysis. Sequencing was done at the University of Maine Sequencing 
Facility by Patty Singer. ISA virus cDNAs in the pGEM-T plasmids were subcloned into 
the DNA vaccine plasmid pcDNA 3.1 (Table 2.4; Invitrogen). Approximately 10 pg of 
plasmid and 20 U &l, restriction enzyme buffer, and 60 pg of bovine serum albumin 
(all New England Biolabs) were mixed and incubated at 37 "C for 4 hr and then at 65 "C 
for 20 min. The plasmid was purified using Qiaquick PCR purification kit as described 
by the manufacturer (Qiagen Inc.) and then treated as described above with the restriction 
enzyme Ml. The pTargetT ISA virus cDNA plasmids were prepared in a similar 
manner using the restriction enzymes m l  and W t l .  The ISA virus cDNA were 
separated by agarose gel electrophoresis and purified using the Qiaquick Gel Extraction 
Kit as described by the manufacturer (Qiagen Inc.). Plasmid pcDNA 3.1 was digested 
with N a l  and -1 or &l and purified using a Qiaquick PCR purification kit as 
described by the manufacturer (Qiagen Inc.). 
The restriction enzyme digested and purified ISA virus cDNA was ligated into 
linearized pcDNA 3.1 by combining the DNAs (3:l insert to vector molar ratio, 
respectively) with Tris-acetate buffer (33 mM Tris-OH, 66 rnM potassium acetate, 10 
Table 2.2 pGEM-T-Vector Constructs 
Segment and Strain Plasmid Name 
Segment 3 (CCBB) 
Segment 3 (Conner) 
Segment 3 (Norway) 
Segment 5 (CCBB) 
Segment 5 (Conner) 
Segment 5 (Norway) 
Segment 7 (CCBB) 
Segment 7 (Conner) 
Segment 7 (Norway) 
Segment 8 (CCBB) 
Segment 8 (Conner) 
Segment 8 (Norway) 
Table 2.3 pTargeT-Vector Constructs 
Segment and Strain Plasmid Name 
Segment 6 (CCBB) 
Segment 6 (Conner) 
Segment 6 (Norway) 
Segnlent 7 (CCBB) 
Segment 7 (Conner) 
Segnlent 7 (Norway) 
Segment 8 (CCBB) 
Segment 8 (Conner) 
Segnlent 8 (Norway) 
Table 2.4 pcDNA3.1 Vector Constructs 
Segment and Strain Plasmid Name 
Segment 3 (CCBB) 
Segment 3 (Conner) 
Segment 3 (Norway) 
Segment 5 (CCBB) 
Segment 5 (Conner) 
Segment 5 (Norway) 
Segment 6 (CCBB) 
Segment 6 (Conner) 
Segment 6 (Norway) 
Segment 7 (CCBB) 
Segment 7 (Conner) 
Segment 7 (Norway) 
Segment 8 (CCBB) 
Segment 8 (Conner) 
Segment 8 (Norway) 
mM magnesium acetate, and 10 mM dithiothreitol, pH 7.4) 4 pg bovine serum albumin 
(New England Biolabs), 8 pM adenosine triphosphate and 1 U T4 ligase (Promega Cop.) 
and incubated at 12 "C for 12- 16 hr. For transformation, the ligation mixture was added 
to E. coli DH5a competent cells and incubated on ice for 15 min, heated at 42 "C for 2 
min, and then incubated on ice for 10 min. The solution was added to 2 ml of LB broth 
(1% Tryptone (Difco), 0.5% Yeast Extract (Difco), and 0.5% NaCl (Fisher)) containing 
0.5% glucose and shaken at 225 rpm at 37 "C for 1 hr. The E. coli cells were centrifuged 
at 6000 g at 4 "C for 3 min using a Beckman 52-21 centrifuge and JA-20 rotor. The cells 
were resuspended, spread on LB agar (1% Tryptone (Difco), 0.5% Yeast Extract (Difco), 
0.5% NaCl (Fisher), and 1.5% Agar (Difco)) containing 100 pg of ampicillidml (Sigma) 
and incubated at 37 "C for 16-24 hr. Plasmid DNA fiom the transfornled E. coli was 
purified using a Qiagen Miniprep Kit as described by the manufacturer (Qiagen Inc.). 
The presence and orientation of the insert was verified by restriction enonuclease 
digestion. 
DNA Vaccine Preparation 
DNA vaccines were prepared using an ammonium acetate precipitation protocol 
(Saporito-Irwin et al., 1997). LB containing 100 pg of ampicillidpl (Sigma) was 
inoculated with a fully-grown culture at a 1:100 ratio and grown 14-16 hours at 37 "C. 
The cells were collected by centrifugation for 5 min at 10000 g at 4 "C in a Beckman J2- 
21 centrifuge using a JAlO rotor and resuspended in solution 1 (25 mM Tris-HC1, pH 7.6, 
10 mM EDTA, pH 8.0, 50 mM glucose). The cells were mixed by gentle rocking and 
incubated on ice for 20 min and solution 2 (200 mM NaOH, 1% SDS) was added. The 
cells were incubated on ice for 10 min and mixed with ice-cold 7.5 M ammonium acetate 
(pH 7.6). The samples were centrifuged for 20 rnin at 25000 g at 4 OC in a Beckman J2- 
21 centrifuge using a JA14 rotor. The supernatant was transferred to a fresh tube and 0.6 
vol of isopropanol was added, samples were incubated at room temperature prior to 
centrifugation for 10 rnin at 10000 g at 4 OC in a Beckman J2-21 centrifuge using a JA14 
rotor. The supernatant was poured off and the pellet containing the crude plasmid DNA 
was resuspended in 2.0 M ammonium acetate followed by a 10 min incubation on ice. 
The plasmid DNA was centrifuged for 10 min at 10000 g at 4 OC in a Beckman J2-21 
centrifuge using a JA20 rotor. The supernatant was transferred to a fresh tube and 0.6 vol 
of isopropanol was added followed by a 10 rnin incubation at RT. The resulting pellet 
was resuspended sterile water and 0.3 mg of RNase A (Invitrogen) was added prior to a 
20 rnin incubation at 37 "C. A total of 0.3 vol of ice-cold 7.5 M ammonium acetate was 
added followed by a 5 min incubation at room temperature. The plasmid DNA was 
centrifuged for 10 rnin at 10000 g at 4 OC in a Beckman J2-21 centrifuge using a JA20 
rotor. The supernatant was transferred to a new tube and 0.6 vol of isopropanol was 
added followed by a 10 min incubation at room temperature. Centrifugation was 
perfomled at 10000 g for 10 rnin at 4 OC in a Beckman J2-21 centrifuge using a JA2O 
rotor. The resulting pellet was washed in 70% ethanol, dned at room temperature, and 
resuspended in sterile water. 
Transfection and Immunohistochemistrv 
The capacity of the plasmids pISA-HANA and pIHNw-G (Anderson and Leong, 
1999) to express the HA or G protein in fish cells was assessed in transfected epithelial 
papillosum cyprini (EPC) cells as described previously (Anderson and Leong, 1999). 
Briefly, EPC cells seeded in six-well plates to 90% confluency were transfected with 1- 
10 pg of the appropriate DNA vector in lipofectanline prepared according to the 
manufacturer's instructions (Invitrogen). The DNA-lipid mixture was incubated with the 
cells for 24 hours at 22°C after which MEM-Hanks containing 5% FBS was added to 
each well. Cells were incubated at 22°C for 72 hours and then fixed with 10% 
fonnaldehyde. Expression of the HA and G proteins in EPC cells was confirmed by 
staining with the monoclonal antibodies 10A3 (Clouthier et al., 2002) and lH8/6A7/5A6 
(Huang et al., 1994, 1996), respectively, as described by Drolet et al. (1994). 
Vaccine Trials 
Trial #1 
An antibody study was performed with 150-160 g specific-pathogen free Rainbow 
trout (Oncorhynchus mykiss) (Clear Springs Foods, Inc., Buhl, Idaho). Groups of 30 fish 
were anaesthetized by immersion in of tricaine methane sulfonate (100 pglml) and 
injected intramuscularly at the base of the dorsal fin with a 200 p1 dose of one of four 
different DNA vaccines (Table 2.5) suspended in phosphate buffered saline (PBS). 
Experimental groups were held separately in W-treated single-pass spring water (15 "C). 
Serum was collected from 10 naive fish at the time of vaccination and at 4, 6, 8, 10, and 
12 weeks post-vaccination from 5 fish per treatment per time point by lethal bleeding 
from the caudal vein. 
* 
Table 2.5. Antibody study in rainbow trout: vaccines and dose. 
Group Vaccine and Dose 
Trial #2 
An IHN virus challenge study to establish vaccine efficacy was performed with 1- 
10 g (mean weight 2 g) specific-pathogen fiee Rainbow trout (Oncorhynchus mykiss) 
(Clear Springs Foods, Inc., Buhl, Idaho). Groups of 150 fish were anaesthetized by 
immersion in 100 pglml of tricaine methane sulfonate and injected intramuscularly at the 
base of the dorsal fin with a 25 p1 dose of one of nine vaccines (Table 2.6) suspended in 
PBS. At 7 days post-vaccination (dpv) duplicate groups of 25 fish fiom each group were 
challenged by waterborne exposure to lo5 plaque forming units (PFU)/ml of IHN virus 
isolate 220-90 (LaPatra et al., 2001) for 60 min with aeration in a volume of water 10 x 
the total weight of the fish. The remaining fish were used as controls. Control groups 
Table 2.6 Efficacy study in rainbow trout: vaccines and dose. 
Group Vaccine and Dose 
were not exposed to IHN virus but were otherwise treated identically. Experimental 
groups were held separately in W-treated single-pass spring water (15 "C) and 
monitored for 21 days for mortality. RPS rates were calculated (RPS = 1 - [% mortality 
of vaccine/% mortality of control] x 100). Significant differences in mortalities were 
detected by the Chi square test using a probability of error threshold (P) value of < 0.05. 
Trial #3 
A study to establish antibody levels during the EVR was performed on 50-100 g 
specific-pathogen fiee Atlantic salmon (Salmo salar). Groups of 45 fish were 
anaesthetized by immersion in 100 pg/ml of tricaine methane sulfonate and injected 
intramuscularly at the base of the dorsal fin with a 200 pl dose of one of four different 
DNA vaccine treatments (Table 2.7) suspended in PBS. Serum was collected fiom 5 
naive fish at the time of vaccination and at 7 and 21 dpv fiom 5 fishltreatment/time point 
by lethal bleeding fiom the caudal vein. 
Trial #4 
An ISA virus challenge study to establish vaccine efficacy was performed on 50- 
100 g specific-pathogen fiee Atlantic salmon (Salmo salar). Groups of 225 fish were 
anaesthetized by immersion in 100 pg/ml of tricaine methane sulfonate. One group was 
vaccinated intramuscularly with a 200 pl dose of a trivalent DNA vaccine (Table 2.8) 
suspended in PBS. The remaining groups were vaccinated by intraperitoneal with a 200 
pl dose of one of the remaining three vaccine treatments (Table 2.8). Serum was 
collected fiom 5 naive fish at the time of vaccination and at 700 and 1,400 degree days 
Table 2.7 Antibody production in Atlantic salmon during EVR: vaccines and 
dose 
Group Vaccine and Dose 
Table 2.8 ISA virus efficacy trial: vaccines and dose 
Group Vaccine and Dose 
pISA-NPNA + pISA-ACNA + PEA-HANA *
whole killed ISA (1 x dose) ** 
recombinant ISA virus peptide ** 
Saline 
* 10 pg of each vaccine 
** Product of  Maine BioTek, Inc. and Microtek Int. Ltd. 
(dd) post-vaccination from 10 fish per treatment per time point by lethal bleeding from 
the caudal vein. At 700 and 1,400 dd post-vaccination 100 fish/vaccine group were 
anaesthetized and challenged by IP injection of 1 ml live ISA virus isolate CCBB at 
1x10~ TCIDSO/ml. RPS rates were calculated (RPS = 1 - [% mortality of vaccine/% 
mortality of control] x 100). Significant differences in mortalities were detected by the 
Chi square test using a probability of error threshold (P) value of < 0.05. 
Trial #5 
An antibody study was performed on 50-100 g specific-pathogen free Atlantic 
salmon (Salmo salar). Groups of 28 fish were anaesthetized by immersion in 100 pg/ml 
of tricaine methane sulfonate. Vaccine groups 1, 2, 3 and 7 were vaccinated 
intramuscularly with a 200 p1 dose of DNA vaccine suspended in PBS (Table 2.9). 
Vaccine groups 4, 5, 6 and 8 were vaccinated by intraperitoneal injection with a 200 p1 
dose of vaccine (Table 2.9). Serum was collected from 25 naive fish at the time of 
vaccination and at 4,6, 10, and 12 dpv from 5 fish/treatment/time point by lethal bleeding 
from the caudal vein. 
Enzyme Linked Immunosorbent Assav (ELISA) 
ELISA was used to measure the binding antibody titer in serum from vaccinated 
fish. The target antigen, untreated IHN or ISA virus, was dried onto the wells of an 
ELISA plate (Costar) overnight at 37°C. After blocking nonspecific binding sites, serial 
dilutions of the primary antisera collected from vaccinated rainbow trout or Atlantic 
Table 2.9 Antibody study in Atlantic salmon: vaccines and dose 
Group Vaccine and Dose 
PISA-NPNA (10 pg) 
~ISA-ACNA (1 0 pg) 
PISA-HANA (10 pg) 
recombinant ISA peptide * 
whole killed ISA (2 x dose) ** 
whole killed ISA (4 x dose) ** 
PLUC (10 
Saline 
* Product of Maine BioTek, Inc. and Microtek Int. Ltd. 
** Product of Microtek Int. Ltd. 
salmon were added to the target antigen and detected with mouse anti-salmonid fish 
immunoglobulin monoclonal antibody (Irnmuno-Precise Antibodies, LTD). Goat anti- 
mouse IgG or IgM conjugated to alkaline phosphatase (Southern Biotechnology 
Associates, Inc) were added followed by 5-Bromo-4-chloro-3-indoyl phosphate (66 
pg/ml) and Nitrotetrazoliurn Blue chloride (59 pg/ml). ELISA measurements were 
expressed as a percentage of IHN virus or ISA virus specific mAb reactivity recorded at 
an absorbance 405 nm. Using this technique we typically detected IHN virus or ISA 
virus specific antibodies in the serum dilution range 1 :20 to 1 :2560. 
Chapter 3 
RESULTS 
ISA Virus DNA Vaccine Transfected Cells. 
The synthesis of HA encoded by the DNA vaccine pISA-HANA was examined by 
immunohistochemical analysis of transfected EPC cells. The pISA-HAN~ transfected 
cells reacted with ISA virus specific rnAblOA3 (Figure 3.1). 
Figure 3.1 Expression of the ISA virus HA protein in cells transfected with pISA-HANA. 
EPC cells were transfected with pISA-HANA and then probed with 10A3, a HA-specific 
monoclonal antibody (A). The cells expressing the HA protein were identified using 
alkaline phosphatase immunocytochemical staining which stains the cells red in the 
photographs. Also shown are cells that were transfected with pPGal and then stained 
with the HA-specific mAb (B). 
ISA Virus DNA Vaccine: Efficacy & Humoral Immune Response 
The efficacy of the ISA virus DNA vaccines was determined in Trial #4 and the 
results are presented in Table 3.1. Atlantic salmon (50-100 g) were vaccinated a trivalent 
DNA vaccine and challenged by intraperitoneal injection with lo7.' tissue culture 
infectious dose (TCID) at 700 dd or lo6 TCID at 1,400 dd of ISA virus. Also included in 
the study were whole killed (wk) and recombinant ISA virus vaccinated fish as well as 
fish inoculated with saline. All of the vaccines were more efficacious at 1,400 dd post- 
vaccination compared to 700 dd. The efficacy of the trivalent ISA virus DNA vaccine in 
Atlantic salmon was less than that observed using an IHN virus G DNA vaccine in 
Atlantic salmon and rainbow trout. In addition, the ISA virus DNA vaccine was less 
efficacious than the whole killed, and recombinant vaccines as detem~ined by the Chi 
square test (Table 3.1). 
The antibody response elicited by the DNA, killed and recombinant ISA vaccines 
was determined in Trial #4 and #5 and measured by ELISA. ISA virus-specific 
antibodies were present 700 and 1,400 dd post vaccination in the DNA vaccinated fish, 
though antibody binding was 23-31% of that obtained using an ISA virus specific 
I 
monoclonal antibody (Figure 3.2). The serum from vaccinated fish that survived ISA 
virus challenge 700 or 1,400 dd post-vaccination had relatively high levels of ISA virus 
specific antibodies. 
Table 3.1 ISA virus efficacy trial: mortality and RPS values 
Vaccine 
Challenge 700 dd Challenge 1400 dd 
% Mortality RPS6O % Mortality RPS4O 
pISA-NPNA, pISA-ACNA, pISA-HANA* 45 25 22 45 
wk ISAV 29 52 n.d.** n.d.** 
rISA 3 1 48 15 63 
Saline 60 - 40 - 
* 10 pg each vaccine 
** Not done 
rlSA 
saline 
700 dd Convalescent 1400 dd Convalescent 
sera sera 
Sera collection ti mpoi nts 
Figure 3.2. Antibody response to ISA virus vaccines in Atlantic salmon. Measured by 
ELISA before ISA virus challenge and at the end of the efficacy trial. Vaccines are as 
follows: 1. wk ISA: whole killed ISA virus vaccine; 2. DNA: trivalent DNA vaccine 
pISA-NPNA, pISA-AcNA, pISA-HANA; 3. rISA: recombinant ISA virus vaccine (product 
of Maine BioTek, Inc. and Microtek Int. Ltd); 4. saline 
Humoral Immune Response to ISA Virus Vaccines 
ISA virus specific antibodies in Atlantic salmon immunized with ISA virus 
DNA, recombinant and whole killed vaccines were measured using an ELISA in Trial #5. 
Relative to mAb 10A3 (Clouthier et al., 2002) and convalescent serum (see Figure 3.2) 
all of the vaccines in this study resulted in low binding titers of the respective sera 
(Figure 3.3). The HA, NP, AC and putative NS encoding DNA vaccines as well as the 
whole killed (4 x dose) ISA virus vaccine elicited ISA virus specific antibodies in 
Atlantic salmon 10-12 weeks post-vaccination. The presence of ISA virus specific 
antibodies in Atlantic salmon in response to the recombinant and whole killed vaccine (2 
x dose) was transient, antibodies being present 4-6 weeks post-vaccination (Figure 3.3). 
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Figure 3.3 Antibody study: antibody production to ISA virus vaccines in Atlantic salmon 
as measured by ELISA. Sera samples were collected at 4,6, 10 and 12 weeks post- 
vaccination. Vaccines 1-8 are as follows: 1, pISA-NPNA; 2, pISA-ACNA; 3, pISA-HANA; 
4, rISA; 5, wk ISA (2 x dose); 6, wk ISA (4 x dose); 7, pLuc; 8, Saline. 
ISA virus specific antibodies in rainbow trout immunized with ISA virus DNA 
vaccines encoding the HA fiom North America or Norway were measured in Trial #1 
using an ELISA (Figure 3.4). The HA fiom Norway pISA-HAN,, and pISA-gNA, 
encoding the putative matrix protein, elicited the highest antibody binding titer 8 weeks 
post-vaccination (wpv). The HA fiom North America, pISA-HANA, elicited antibody 
titers beginning 4 wpv and lasting for at least 12 wpv. 
4 6 8 10 12 
Weeks post-vaccination 
Figure 3.4 Antibody study: antibody production to ISA virus vaccines in rainbow trout as 
measured by ELISA. Sera samples were collected at 4,6, 8, 10 and 12 weeks post- 
vaccination. 
EVR: IHN and ISA Virus DNA Vaccines 
The ISA and IHN virus vaccines did not elicit a measurable antibody response in 
Atlantic salmon or rainbow trout at 7 or 21 d post-vaccination as determined in Trial #3 
by ELISA (data not shown). These data extend the observations of LaPatra et al. that fish 
antibodies do not mediate the early antiviral response (EVR) since they are not detectable 
in fish sera until 3-4 weeks afier vaccination. The NS protein of influenza A, the 
prototypic orthomyxovirus, prevents activation of NF-kB and induction of alphabeta 
interferon (Wang et al., 2000). An antiviral interferon response may be an important 
mechanism of immunity elicited by the IHN virus G DNA vaccine. To determine if the 
NS protein of ISA virus could modulate the EVR by interfering with the putative 
interferon response elicited by the pIHNw-G vaccine we co-administered ~ 1 s A - 7 ~ ~  or 
~ 1 s A - 8 ~ ~  with pIHNw-G and challenged with IHN virus 7 and 28 d post-vaccination. 
The ISA virus proteins had no effect on the EVR elicited by pIHNw-G (Table 3.2). 
Table 3.2. IHN virus efficacy trial: % mortality and RPS values 
Challenge 7 dpv Challenge 28 dpv 
Vaccine and Dose 
% Mortality RPS % Mortality RPS 
* 10 pg each vaccine 
Chapter 4 
DISCUSSION 
This study was designed to measure the efficacy of ISA virus DNA vaccines 
encoding the HA, AC or NP (derived fiom North American or Norwegian ISA virus 
isolates) and the antibody response these vaccines elicited in Atlantic salmon and 
rainbow trout. The efficacy of the trivalent DNA vaccine was compared to the efficacy 
of a prototype recombinant ISA virus vaccine and a whole killed ISA virus vaccine. The 
ISA virus HA and NP were selected as vaccine target antigens based on the finding that 
Atlantic salmon that survive ISA virus challenge produce relatively large amounts of 
anti-HA and NP antibodies (Clouthier et al., 2002). The DNA vaccine encoding the ISA 
virus HA was active in transfected EPC cells, serving as the template for HA protein 
synthesis (Figure 3.1). Passive transfer of anti-ISA virus antibodies in serum collected 
fiom convalescent fish to naNe Atlantic salmon protects the fish from ISA virus infection 
(unpublished data). The results suggest that HA specific virus-neutralizing antibodies are 
important in a successful immune response to ISA virus (Fak & Dannevig, 1995). ISA 
virus AC (P3) was included in the trivalent vaccine because the protein may be located 
on the surface of the virion and as such might be an important antigen functioning similar 
to the NA of influenza virus. 
Antigenic drift and shift were also considered when selecting vaccine candidates 
for an ISA virus vaccine. Influenza virus undergoes antigenic shifts resulting in disease 
pandemics and antigenic drift that constitutes microheterogeneity within virus strains 
(Webster et al., 1981). Antigenic shift has not been reported for ISA virus but distinct 
differences in nucleic acid and amino acid sequence have been observed upon 
comparison of the HA of North American and European ISA virus isolates (Krossoy et 
al., 2001b). Further, ISA virus isolates from Nova Scotia, Canada, have been reported to 
be more closely related to European isolates than they are to viral isolates fiom New 
Brunswick, Canada and Maine (Ritchie et al., 2001b). The potential for antigenic shift in 
ISA virus isolates was addressed with the inclusion of NP in the ISA virus trivalent DNA 
vaccine, the protein most likely to be involved in eliciting protection against heterologous 
virus. In influenza infections, the primary antiviral activity of the helper T cell is to 
provide help to B cells to produce antiviral antibodies (Scherle et al., 1992) whereas the 
primary role of the CTL response is in clearance of an established infection (McMichael 
et al., 1983). The latter is directed mainly against the highly conserved NP and is the 
basis for the cross-reactivity generated against all influenza virus subtypes in mice and 
man (MacKenzie et al., 1989). The amino acid sequence of the putative nucleocapsid 
protein from the ISA virus isolate CCBB shares 96.6% identity to the NP protein 
sequence from Scottish isolate 390198 (Clouthier et al., 2002). The high sequence 
conservation (compared to 70-85% for the other proteins) suggests that the ISA virus NP 
protein may be a type-specific, cross-protective antigen, like the NP protein of influenza 
viruses (Lamb & Krug, 1996). 
The relative percentage survival of fish immunized with the trivalent DNA 
vaccine, pISA-NPNA, pISA-AcNA, pISA-HANA was 25% when the fish were inoculated 
with live virus 700 dd post-vaccination and 46% 1,400 dd post-vaccination (Table 3.1). 
The efficacy of the ISA virus vaccine is much less than has been reported for influenza 
virus DNA vaccines encoding the HA, NA or NP (Ulrner et al., 1993; Chen et al., 1999). 
The efficacy of the influenza virus DNA vaccine is dose dependent; increasing the 
vaccine dose increases the efficacy of the vaccine (Ulmer et al., 1994). Whether 
increasing the dose or number of boost would increase the efficacy of the ISA virus DNA 
vaccine must be determined in future studies. The ISA virus DNA vaccine is 
considerably less efficacious than reported for DNA vaccines encoding the 
Novirhabdovirus G protein. For example, the efficacy of a single dose (0.1 - 1 pg) of the 
MN virus G protein DNA vaccine pIHNw-G in Atlantic salmon has been shown 
previously to be 90-100% (Kurath et al., 2001) and in this study was 90%. More studies 
will be required to determine the optimum ISA virus DNA vaccine dose. 
The trivalent ISA virus DNA vaccine was not as efficacious as the whole killed or 
recombinant ISA virus vaccine. The reason for the differences in efficacy of the vaccine 
types is multivariant and the data presented here do not address the question. However, 
the anlount of serum antibody in Atlantic salmon vaccinated with the DNA, whole killed 
or recombinant ISA virus vaccines was low at 700 and 1,400 dd post vaccination. In 
contrast, a greater amount of anti-ISA virus antibodies are present in convalescent fish 
(Figure 3.2). These results indicate that the humoral immune response is important for 
protection against ISA but the relative contribution of binding and neutralizing antibodies 
to the immunoprotective response is unknown and will be addressed in future studies. 
Other studies have shown that convalescent fish are resistant to live ISA virus challenge 
and that the serum from convalescent fish, when injected into nayve fish, confers 
protection to subsequent exposure to ISA virus (unpublished results). Studies with whole 
killed and recombinant influenza virus vaccines show that the HA and NA elicit an 
immunoprotective response. The mediators of resistance to influenza virus in mice 
include binding and neutralizing antibodies (Epstein et al., 1993). The titer of the HA or 
NA-specific antibodies is directly proportional to efficacy of influenza vaccines 
(Clements et al., 1986; Murphy et al., 1972). The relatively low antibody binding titers 
elicited by the vaccines in this study may account for their performance and suggests that 
strategies to boost the antibody titer in vaccinated fish may improve the efficacy of this 
vaccine. 
The data indicate that IHN and ISA virus DNA vaccines encoding viral 
glycoproteins are not equivalent in their ability to stimulate an immunoprotective 
response in Atlantic salmon. The IHN virus G protein encoding DNA vaccine, pIHNw- 
G, elicits a non-specific, cross-reactive, immunoprotective response (EVR) 4-7 d post- 
vaccination (LaPatra et al., 2001). Neutralizing or binding antibodies are not required for 
the EVR. In addition, the pIHNw-G vaccine elicits a specific viral response (SVR) 
beginning approximately 4 wk post-vaccination. The appearance of serum antibodies 
coincides with the loss of the EVR elicited by pIHNw-G and the appearance of the SVR. 
The SVR elicited by pIHNw-G provides 90- 100% RPS 1-3 months post-vaccination, 
69% RPS 6 mo post-vaccination and 65% RPS 13 mo post vaccination (Kurath et al., 
2001). To deternine if ISA virus proteins can elicit an EVR or a SVR, rainbow trout 
were vaccinated with ISA virus DNA vaccines and challenged with IHN virus 7 or 28 d 
post-vaccination (Table 3.2). The ISA virus DNA vaccines encoding the HA, NP or AC 
proteins did not elicit an EVR that was immunoprotective against heterologous challenge 
with IHN virus. The data from these studies support the idea that the Novirrhabdovirus 
G protein in the DNA vaccine plays an important, possibly unique role in eliciting an 
EVR. 
The NS protein of influenza A, the prototypic orthomyxovirus, prevents activation 
of NF-kB and induction of alphatbeta interferon (Wang et al., 2000). An antiviral 
interferon response may be an important mechanism of immunity elicited by the IHN 
virus G DNA vaccine. For example, there is an increase in proteins mediating cellular 
responses to interferon in fish vaccinated with DNA vaccines encoding novirhabdovirus 
G proteins (Boudinot et al., 1999; 2001; Collet & Secombes, 2001; Hansen & LaPatra, 
2002; Trobndge & Leong, 1995; Trobndge et al., 1997). Due to the similarities between 
influenza viruses and the ISA virus it is possible that the ISA virus possesses a gene that 
has a similar immunosuppressive finction. A recent study by Bienng et al. (2002) 
suggests that the NS protein of ISA virus may possibly be encoded by genome segment 7 
and the matrix protein by genome segment 8. Co-administration of ~ 1 s A - 7 ~ ~  or pISA- 
with pIHNw-G had little effect on the EVR upon challenge with IHN virus. In the 
framework of this study, the putative NS protein of ISA virus does not seem to affect the 
EVR. Further studies will be required to determine if interferon is involved in the EVR. 
In summary, a group of Atlantic salmon vaccinated with the trivalent ISA virus 
DNA vaccine we developed, resulted in an RPS of 25% when the fish were inoculated 
with live virus 700 dd post-vaccination and 46% 1,400 dd post-vaccination. The efficacy 
of the trivalent ISA virus DNA vaccine was modest when compared to the efficacy of a 
whole killed or recombinant ISA virus vaccine. In addition, the efficacy of the ISA virus 
DNA vaccines was much less than the immunoprotection conferred by the vaccine 
pIHNw-G in rainbow trout against IHN virus challenge. None of the vaccines elicited a 
pronounced antibody response. The poor antibody response may be related to the 
relatively modest efficacy of the ISA virus vaccine, which contrasts with IHN virus 
vaccines for which little correlation exist between immunoprotection and seroconversion. 
Finally, the trivalent ISA virus vaccine did not elicit an immunoprotective EVR in 
rainbow trout suggesting that the fish Novirhabdovirus G protein may have intrinsic 
molecular patterns recognized by the innate and adaptive arms of the immune system. 
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